Rznomics Inc., a South Korea based biopharmaceutical company, announced on Friday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RZ-001 intended for the treatment of patients with Hepatocellular carcinoma (HCC).
The ODD allows the product to receive seven years of marketing exclusivity upon product approval, exemption from user fee and tax credits. It is also expected to provide access to specialised regulatory assistance from the FDA's Office of Orphan Products Development (OOPD).
Seong-Wook Lee, Rznomics CEO and founder, said, 'This FDA Orphan Drug Designation further underlines the potential of our pipeline to expeditiously address the current unmet medical needs of patients with Hepatocellular Carcinoma.'
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment